Clinical trial
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
NCT02606045 is registered in ClinicalTrials.gov with Margaret Ragni as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
- Lead sponsor
- Margaret Ragni
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- February 7, 2019
- Completion date
- August 30, 2022
- Enrollment
- 39 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.